Do Protagonist Therapeutics' (PTGX) Derisked Drugs Have Blockbuster Potential? [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
A copy of the letter can be downloaded here . The Strategy underperformed the Russell 2000 Growth Index in the fourth quarter, after a strong first three quarters of 2025. Market's overreactions to earnings disappointments in the technology sector and a biotech rally drove the relative underperformance of the Strategy in the quarter. In a volatile year, dominated by a narrow set of themes, the small caps failed to outperform large caps, echoing the past two years, although broadening appears to be emerging. Heading to 2026, the Strategy is optimistic about the favorable backdrop for small-cap growth stocks following years of narrow market leadership and performance disparities. Please review the Strategy's top five holdings to gain insights into their key selections for 2025. In its fourth-quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy highlighted stocks like Protagonist Therapeutics, Inc. (NASDAQ: PTGX ). Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopha
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an "overweight" rating on the stock.MarketBeat
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/26/26 - Form 144
- 3/26/26 - Form 144
- PTGX's page on the SEC website